Internal Medicine, Medical Oncology · New York, NY
NPI
1952460172
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (646) 422-4612
Groups this clinician bills Medicare through
Medicare paid, 2024
$125K
1,425 services
Medicare patients, 2024
338
Average age 76
Drug cost, 2024
$6.8M
1,376 prescriptions
Company payments, 2025
$14K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel C Danila was code 99215 (office e&m - established), 612 times for 239 patients. In total Daniel C Danila billed 1,425 services in 12 codes, and Medicare paid $125K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-08-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 612 | 239 | $127.42 | $78K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 364 | 224 | $14.23 | $5,181 |
| 99214 Office E&M - Established | Office | 271 | 180 | $85.34 | $23K |
| 99205 Office E&M - New | Office | 51 | 51 | $154.53 | $7,881 |
| 99233 Hospital E&M - Subsequent | Facility | 49 | 15 | $102.62 | $5,029 |
| 99213 Office E&M - Established | Office | 26 | 26 | $65.20 | $1,695 |
By year: 2022 $106K for 1,010 services; 2023 $108K for 1,034 services; 2024 $125K for 1,425 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel C Danila prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 348 prescriptions and refills. In total Daniel C Danila wrote 1,376 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 348 | 358 | 57 | $4.8M |
| Prednisone Generic | 309 | 361 | 54 | $1,228 |
| Abiraterone Acetate Generic | 204 | 224 | 37 | $385K |
| Orgovyx Relugolix | 181 | 181 | 32 | $468K |
| Tamsulosin Hcl Generic | 58 | 132 | 20 | $1,216 |
| Nubeqa Darolutamide | 50 | 50 | Under 11 | $666K |
| Gabapentin Generic | 18 | 18 | Under 11 | $228 |
| Lynparza Olaparib | 17 | 17 | Under 11 | $288K |
| Erleada Apalutamide | 17 | 17 | Under 11 | $181K |
| Bicalutamide Generic | 16 | 18 | Under 11 | $180 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 16 | 26 | Under 11 | $283 |
| Ondansetron Hcl Generic | 15 | 15 | Under 11 | $154 |
| Myrbetriq Mirabegron | 15 | 15 | Under 11 | $6,527 |
| Oxycodone Hcl Generic | 14 | 14 | Under 11 | $69.26 |
Brand drugs: 639 claims; generic drugs: 737 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel C Danila $14K ($14K in general payments such as food, travel and fees and $330 for research) from 9 companies. The largest payer was Janssen Biotech, Inc. with $5,543.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 12 | $5,543 |
| Astellas Pharma Global Development 4503.T | 2 | $3,544 |
| Pfizer Inc. PFE | 4 | $2,750 |
| Janssen Scientific Affairs, LLC JNJ | 4 | $1,947 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $101 |
| Sumitomo Pharma America, Inc. 4506.T | 1 | $62.65 |
| Amgen Inc. AMGN | 1 | $47 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $16.96 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.